When you're fighting a gynecologic cancer like cervical, endometrial, or ovarian cancer, you and your doctors want every possible tool. Researchers looked at whether adding a common, inexpensive diabetes drug called metformin to standard treatments could be one of those tools. They combined data from five clinical trials involving 705 patients. The bottom line: adding metformin did not significantly improve how long patients lived without their cancer getting worse (progression-free survival) or how long they lived overall (overall survival).
Digging deeper, the analysis found no survival benefit for women with cervical or endometrial cancers. For ovarian cancer, the picture was murkier. One study within the analysis suggested metformin might help delay cancer progression, but the result came with a big asterisk. The statistical confidence interval was very wide, which means the finding isn't reliable enough to bank on—it could easily be due to chance.
It's important to know this review didn't report on side effects or how well patients tolerated the combined treatment, so we don't have the full safety picture. The researchers also noted the major limitation with the potential ovarian cancer finding: that wide confidence interval makes it shaky ground for any conclusions. Right now, the combined evidence from these trials simply doesn't show that metformin boosts survival for these cancers. The search for effective new treatment combinations continues.